Canada HIV Therapeutics Market Analysis Report [2022-30] I Insights10

Canada HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Canada HIV therapeutics market will reach a value of $1.4 Bn from $1.1 Bn in 2022, growing at a CAGR of 2.7% during 2022-2030. The market is primarily dominated by local players such as Trillium Therapeutics, AbCellera Biologics, and Aptevo Therapeutics. The market is driven by innovation in research and development, increasing prevalence, and good governance. The HIV therapeutics market in Canada is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10CAPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada AUTHOR: Dr. Vishwa Modhia

Buy Now

Canada HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Canada HIV therapeutics market will reach a value of $1.4 Bn from $1.1 Bn in 2022, growing at a CAGR of 2.7% during 2022-2030.

Antiretroviral therapy (ART) is widely accessible to people living with HIV in Canada, where the public healthcare system manages and treats HIV. To suppress the virus and stop the development of AIDS, ART typically consists of a combination of medications that each target a different stage of the HIV replication cycle.

The Canadian HIV Guidelines advise patients who have never received treatment to combine at least three medications from at least two different classes. The medications used to treat HIV in Canada include entry inhibitors, integrase inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), and a new class of medications known as "INSTI."

canada HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers Analysis

HIV infection rates are rising. More than 62,000 Canadians were HIV positive as of 2020. In Canada, 6.6 people acquire HIV each day. In 2017, the provinces with the most newly diagnosed HIV cases in Canada were Ontario, Quebec, and British Columbia.

Canada is currently serving a 2020–2022 term as a member of the UNAIDS Programme Coordinating Board and has donated more than $100 Mn in financial support to UNAIDS since 1996. Canadian contributions to UNAIDS' core funding total $20 Mn between 2017 and 2022.

Market Restraints

There is a lack of awareness and understanding of HIV AIDS among the people of Canada. Even in 2022, despite the existence of treatments that can help prevent transmission and improve quality of life, there is still a lot of misinformation about HIV.

In the community, AIDS and HIV infection continue to carry a stigma. Even though Canada is one of the developed countries, people still stigmatize those who have HIV. These elements may limit the market expansion for HIV medications in Canada.

Competitive Landscape

Key Players

Trillium Therapeutics (CAN)
AbCellera Biologics (CAN)
Aptevo Therapeutics (CAN)
Centre for Commercialization of Regenerative Medicine (CAN)
GlaxoSmithKline
Janssen Pharmaceuticals
Gilead
ViiV Healthcare
AbbVie
Novartis
Pfizer

Regulations and Reimbursement

Health Canada is the regulatory authority responsible for the oversight of a variety of health products and services. Within Health Canada, the Biologics and Genetic Therapies Directorate (BGTD) is the Canadian federal authority dedicated to the regulation of biological drugs

In Canada, private insurance paid for the majority of PrEP prescriptions, followed by public insurance (46%), and cash (1%). The Federal Initiative to Address HIV/AIDS in Canada is a key element of the Government of Canada’s comprehensive approach to HIV/AIDS. The Federal Initiative provides funding for prevention and support programs reaching key priority populations, as well as research, surveillance, public awareness, and evaluation.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.